Wesam M Salama1 
,
Sabry A El-Naggar1,
Barakat M ALRashdi2
For correspondence:- Wesam Salama Email: wesam.salama2010@gmail.com
Accepted: 27 July 2023 Published: 31 August 2023
Citation: Salama WM, El-Naggar SA, ALRashdi BM. In vivo anti-tumor effect of Egyptian scorpion Leiurus quinquestriatus venom in Ehrlich ascites carcinoma-bearing mice. Trop J Pharm Res 2023; 22(8):1635-1643 doi: 10.4314/tjpr.v22i8.15
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the anti-tumor efficacy of scorpion Leiurus quinquestriatus venom (LQV) in Ehrlich ascites carcinoma (EAC) mouse model.
Methods: Mice were divided into 4 groups (n = 8), with Group 1 as negative control. Groups 2 to 4 mice were inoculated with EAC cells (1 x 106/mouse) intraperitoneally (ip). Group 2 mice were untreated while groups 3 and 4 mice were injected with 2 mg/kg of cisplatin (Cis) and 0.025 mg/kg of LQV ip, respectively, for 7 days. Tumor profile, as well as hematological and biochemical analyses were carried out.
Results: Tumor volume and tumor cell counts decreased significantly (p < 0.05) following LQV treatment. Also, LQV potentiated necrosis, apoptosis and arrested tumor cells in the G0 and S-phases. Furthermore, it upregulated apoptotic-related gene (Bax and caspase-3) ex
Conclusion: LQV has potential anti-tumor activity against EAC cells in mouse models. Therefore, it should be further investigated in vivo as an anti-tumor agent.
Fulltext in PDF